No Data
No Data
Amicus Therapeutics' Earnings Call Highlights Growth and Strategic Moves
Amicus Therapeutics | 10-Q: Quarterly report
Amicus Therapeutics Down Over 12%, on Pace for Largest Percent Decrease Since January 2022 -- Data Talk
Amicus Therapeutics Turns to Non-GAAP Q1 Earnings, Revenue Rises; Shares Down
Express News | Amicus Therapeutics Shares Are Trading Lower After the Company Reported Mixed Q1 Financial Results
Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates